Approval is supported by positive results from three completed randomized, placebo-controlled phase III trials that enrolled more than 1000 subjects in the US and Europe Hugel America, Inc., a growth-focused
Hugel America, Inc. Announces U.S. FDA Acceptance of Biologics License Application (BLA) for LetibotulinumtoxinA for Injection to Treat Glabellar (Frown) Lines prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.